| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf6afdc16ee5518854b0e3299d734662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_397384a6d230e34cf9e18e9c7d9b0a03 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-627
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50f2ad17d301f63465246ebd27415fde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d769a43ab972c213c4c11af64f57924
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adfe4be5efffe7cf3c38db8d8795261a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea33084ef6fa0d4828bf7054f919b620
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b230a573e3a7b8865ca9408fef7564c |
| publicationDate |
2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2020230292-A1 |
| titleOfInvention |
Individualized vaccines for cancer |
| abstract |
The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of ntumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present ninvention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a nfirst immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune nresponse against one or more tumor antigens in the patient wherein the second immune response is specific for ncancer specific somatic mutations present in cancer cells of the patient. |
| priorityDate |
2012-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |